During Trial Design, Balancing Surrogate Markers With Patient-Reported Outcomes as Trial Endpoints

Speaker(s)

• DB

  Donna Buckley, MD

  FDA
  Silver Spring, Maryland, United States

  Disclosure(s): No financial relationships to disclose

  Slides